Skip to content

fMRI mechanism of in-home tDCS in the treatment of cognitive impairment

fMRI mechanism of in-home tDCS in the treatment of cognitive impairment

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400090265
Enrollment
Unknown
Registered
2024-09-26
Start date
2024-10-20
Completion date
Unknown
Last updated
2024-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cognitive impairment

Interventions

experimental group:tDCS therapy
control group:sham stimulation

Sponsors

Affiliated Hospital of Hangzhou Normal University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Over 60 years old; 2. Meet the possible diagnostic criteria for MCI or NIA-AA mild AD; 3. The Concise Mental State Examination Scale (MMSE) score is greater than 20 points; 4. Use a stable dose of therapeutic drugs for at least 3 months prior to tDCS treatment; 5. Passed tDCS safety screening, no metal implanted DBS electrode, no epilepsy and other neuropsychiatric diseases, no motor system diseases; 6. Pass MRI safety screening, have no history of head trauma and serious heart disease, and can complete MRI scan; 7. Sign the subject informed consent.

Exclusion criteria

Exclusion criteria: 1. There are obvious adverse reactions; 2. Actively quit the test; 3. Unable to judge the efficacy or incomplete data affecting the efficacy or safety judgment; 4. Head movement of all fMRI images, translational >3mm, rotational >3°

Design outcomes

Primary

MeasureTime frame
Cognitive function;fMRI;

Countries

China

Contacts

Public ContactDanning Lou

Affiliated Hospital of Hangzhou Normal University

candy2379363@163.com+86 136 1655 7056

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026